Replies to post #202527 on Biotech Values

[DewDiligence]

EGRX addendum—MDCO’s Orange Book patents on Angiomax (which the CAFC found valid today) run until Jan 2029:

http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020873&Product_No=001&table1=OB_Rx

Angiomax sold about $600M per annum in the US before it initially went generic; so, now that MDCO’s patents have been found valid after all, Kangio, which has several advantages relative to Angiomax, represents a pretty big market opportunity for EGRX.